tiprankstipranks
Addus Homecare (ADUS)
NASDAQ:ADUS
US Market
ADUS
Addus Homecare
RESEARCH TOOLSreports
Want to see ADUS full AI Analyst Report?

Addus Homecare (ADUS) Stock Forecast & Price Target

364 Followers
See the Price Targets and Ratings of:

ADUS Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
8 Buy
1 Hold
1 Sell
Based on 10 analysts giving stock ratings to
Addus
Homecare
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ADUS Stock 12 Month Forecast

Average Price Target

$127.43
▲(10.18% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Addus Homecare in the last 3 months. The average price target is $127.43 with a high forecast of $145.00 and a low forecast of $96.00. The average price target represents a 10.18% change from the last price of $115.65.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"$88","117":"$117","146":"$146","102.5":"$102.5","131.5":"$131.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":127.42857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$127.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$96.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,102.5,117,131.5,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,115.48,117.75076923076924,120.02153846153847,122.2923076923077,124.56307692307692,126.83384615384615,129.10461538461539,131.3753846153846,133.64615384615385,135.91692307692307,138.18769230769232,140.45846153846153,142.72923076923075,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,115.48,116.39912087912089,117.31824175824177,118.23736263736264,119.15648351648352,120.0756043956044,120.99472527472528,121.91384615384615,122.83296703296703,123.75208791208792,124.6712087912088,125.59032967032967,126.50945054945055,{"y":127.42857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,115.48,113.98153846153846,112.48307692307692,110.98461538461538,109.48615384615385,107.98769230769231,106.48923076923077,104.99076923076923,103.49230769230769,101.99384615384615,100.49538461538461,98.99692307692308,97.49846153846154,{"y":96,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":104.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.89,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.39,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.32,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.56,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.45,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.25,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":115.48,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$145.00Average Price Target$127.43Lowest Price Target$96.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stephens Analyst forecast on ADUS
Unknown Analyst
Stephens
Not Ranked
Stephens
$136
Buy
17.60%
Upside
Reiterated
08/05/26
Addus Homecare (ADUS) Receives a Buy from Stephens
RBC Capital Analyst forecast on ADUS
Ben Hendrix
RBC Capital
RBC Capital
$130→$134
Buy
15.87%
Upside
Reiterated
08/05/26
Addus HomeCare price target raised to $134 from $130 at RBC CapitalAddus HomeCare price target raised to $134 from $130 at RBC Capital
Truist Financial Analyst forecast on ADUS
Clarke Murphy
Truist Financial
Truist Financial
$135
Buy
16.73%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Danaher (DHR), Vertex Pharmaceuticals (VRTX)
Bank of America Securities Analyst forecast on ADUS
Joanna Gajuk
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on ADUS
Ryan Langston
TD Cowen
TD Cowen
$131
Buy
13.27%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Barclays Analyst forecast on ADUS
Andrew Mok CFA
Barclays
Barclays
$96
Sell
-16.99%
Downside
Reiterated
08/04/26
Barclays Remains a Sell on Addus Homecare (ADUS)
BMO Capital Analyst forecast on ADUS
Sean Dodge
BMO Capital
BMO Capital
$110→$115
Hold
-0.56%
Downside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Addus Homecare (NASDAQ: ADUS) and Henry Schein (NASDAQ: HSIC)
William Blair Analyst forecast on ADUS
Jared Haase
William Blair
William Blair
―
Buy
―
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and Addus Homecare (NASDAQ: ADUS)
UBS Analyst forecast on ADUS
A.J. Rice
UBS
UBS
$145
Buy
25.38%
Upside
Reiterated
06/24/26
Addus Homecare: Buy Rating Reiterated on Steady Volume Momentum, Acquisition Outperformance, and Double-Digit Growth Ambitions
KeyBanc Analyst forecast on ADUS
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Buy
―
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on ADUS
Michael Wiederhorn
Oppenheimer
Oppenheimer
$155
Buy
34.03%
Upside
Assigned
05/06/26
Oppenheimer Sticks to Their Buy Rating for Addus Homecare (ADUS)
Raymond James Analyst forecast on ADUS
John Ransom
Raymond James
Raymond James
―
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)
Citizens JMP Analyst forecast on ADUS
Constantine Davides
Citizens JMP
Citizens JMP
$150→$142
Buy
22.78%
Upside
Reiterated
05/06/26
Addus HomeCare price target lowered to $142 from $150 at CitizensAddus HomeCare price target lowered to $142 from $150 at Citizens
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stephens Analyst forecast on ADUS
Unknown Analyst
Stephens
Not Ranked
Stephens
$136
Buy
17.60%
Upside
Reiterated
08/05/26
Addus Homecare (ADUS) Receives a Buy from Stephens
RBC Capital Analyst forecast on ADUS
Ben Hendrix
RBC Capital
RBC Capital
$130→$134
Buy
15.87%
Upside
Reiterated
08/05/26
Addus HomeCare price target raised to $134 from $130 at RBC CapitalAddus HomeCare price target raised to $134 from $130 at RBC Capital
Truist Financial Analyst forecast on ADUS
Clarke Murphy
Truist Financial
Truist Financial
$135
Buy
16.73%
Upside
Reiterated
08/05/26
Analysts' Top Healthcare Picks: Danaher (DHR), Vertex Pharmaceuticals (VRTX)
Bank of America Securities Analyst forecast on ADUS
Joanna Gajuk
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
08/04/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
TD Cowen Analyst forecast on ADUS
Ryan Langston
TD Cowen
TD Cowen
$131
Buy
13.27%
Upside
Assigned
08/04/26
Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Barclays Analyst forecast on ADUS
Andrew Mok CFA
Barclays
Barclays
$96
Sell
-16.99%
Downside
Reiterated
08/04/26
Barclays Remains a Sell on Addus Homecare (ADUS)
BMO Capital Analyst forecast on ADUS
Sean Dodge
BMO Capital
BMO Capital
$110→$115
Hold
-0.56%
Downside
Reiterated
08/04/26
Analysts Offer Insights on Healthcare Companies: TransMedics Group (NASDAQ: TMDX), Addus Homecare (NASDAQ: ADUS) and Henry Schein (NASDAQ: HSIC)
William Blair Analyst forecast on ADUS
Jared Haase
William Blair
William Blair
―
Buy
―
Reiterated
08/03/26
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (NASDAQ: OCUL) and Addus Homecare (NASDAQ: ADUS)
UBS Analyst forecast on ADUS
A.J. Rice
UBS
UBS
$145
Buy
25.38%
Upside
Reiterated
06/24/26
Addus Homecare: Buy Rating Reiterated on Steady Volume Momentum, Acquisition Outperformance, and Double-Digit Growth Ambitions
KeyBanc Analyst forecast on ADUS
Matthew Gillmor CFA
KeyBanc
KeyBanc
―
Buy
―
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Oppenheimer Analyst forecast on ADUS
Michael Wiederhorn
Oppenheimer
Oppenheimer
$155
Buy
34.03%
Upside
Assigned
05/06/26
Oppenheimer Sticks to Their Buy Rating for Addus Homecare (ADUS)
Raymond James Analyst forecast on ADUS
John Ransom
Raymond James
Raymond James
―
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)
Citizens JMP Analyst forecast on ADUS
Constantine Davides
Citizens JMP
Citizens JMP
$150→$142
Buy
22.78%
Upside
Reiterated
05/06/26
Addus HomeCare price target lowered to $142 from $150 at CitizensAddus HomeCare price target lowered to $142 from $150 at Citizens
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
ZURAZura Bio
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Addus Homecare

3 Months
Ryan LangstonTD Cowen
Success Rate
14/20 ratings generated profit
70%
Average Return
+5.85%
Copying Ryan Langston's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +5.85% per trade.
1 Year
Michael WiederhornOppenheimer
Success Rate
28/42 ratings generated profit
67%
Average Return
+17.62%
Copying Michael Wiederhorn's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +17.62% per trade.
2 Years
John RansomRaymond James
Success Rate
11/14 ratings generated profit
79%
Average Return
+21.35%
Copying John Ransom's trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +21.35% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ADUS Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
2
2
1
0
Buy
10
10
11
11
8
Hold
1
1
1
1
1
Sell
2
3
2
3
2
Strong Sell
0
0
0
0
0
total
14
16
16
16
11
In the current month, ADUS has received 8 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. ADUS average Analyst price target in the past 3 months is 127.43.
Each month's total comprises the sum of three months' worth of ratings.

ADUS Financial Forecast

ADUS Earnings Forecast

Next quarter’s earnings estimate for ADUS is $1.79 with a range of $1.75 to $1.86. The previous quarter’s EPS was $1.73. ADUS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year ADUS has Performed in-line its overall industry.
Next quarter’s earnings estimate for ADUS is $1.79 with a range of $1.75 to $1.86. The previous quarter’s EPS was $1.73. ADUS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year ADUS has Performed in-line its overall industry.

ADUS Sales Forecast

Next quarter’s sales forecast for ADUS is $388.70M with a range of $386.43M to $390.37M. The previous quarter’s sales results were $377.42M. ADUS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year ADUS has Performed in-line its overall industry.
Next quarter’s sales forecast for ADUS is $388.70M with a range of $386.43M to $390.37M. The previous quarter’s sales results were $377.42M. ADUS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year ADUS has Performed in-line its overall industry.

ADUS Stock Forecast FAQ

What is ADUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Addus Homecare’s 12-month average price target is 127.43.
    What is ADUS’s upside potential, based on the analysts’ average price target?
    Addus Homecare has 10.18% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ADUS a Buy, Sell or Hold?
          Addus Homecare has a consensus rating of Moderate Buy which is based on 8 buy ratings, 1 hold ratings and 1 sell ratings.
            What is Addus Homecare’s price target?
            The average price target for Addus Homecare is 127.43. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $145.00 ,the lowest forecast is $96.00. The average price target represents 10.18% Increase from the current price of $115.65.
              What do analysts say about Addus Homecare?
              Addus Homecare’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of ADUS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.